A randomized controlled study has shown comparable efficacy of neoadjuvant AI versus chemotherapy for ER-positive, HER2-negative, postmenopausal breast cancer with regard to pCR and breast conservation rates, but significantly less adverse events with AI than with chemotherapy [8]. This evidence concerns the gene ESR1 and breast carcinoma.